The Company enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from related parties and investments in ordinary shares.
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.
For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the reporting date.
Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Convertible Loan Notes
On 1 January 2017, the company issued €121,919 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 5%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $112,397
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.27
On 1st November 2017, the company issued €50,000 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 5%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $44,567
- Equity component: $27,215
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.27
On 24th October 2019, the company issued €500,000.00 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 2%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $404,769
- Equity component: $149,204
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.27
On 23rd March 2020, the company issued €500,000.00 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 2%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: €401,640
- Equity component: $148,138
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.27
On 10th November 2022, the company issued $1,000,000 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 5%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $973,694
- Equity component: $141583.45
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.31
On 15th March 2023, the company issued $100,000 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 5%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $97,769
- Equity component: $16,585
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.31
On 4th April 2023, the company issued $100,000 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 5%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $97,661
- Equity component: $11,852
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.31
On 5th April 2023, the company issued $800,000 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 5%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $759,322
- Equity component: $116,678
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.31
On 24th April 2023, the company issued $70,000 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 5%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $66,280
- Equity component: $10,185
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.31
On 30th March 2024, the company issued $300,000 of convertible loan notes, maturing on 18th March 2025, with an annual interest rate of 2%. The loan notes are convertible into ordinary shares of the company at any time before maturity at the option of the holder. The interest is accrued annually.
- Liability component: $298,225
- Equity component: $28,775
- Conversion terms: The loan, including the accrued interest is converted into £0.0001 shares at a price per share of £0.38